Drugs / Recombinant Human Papillomavirus Bivalent Vaccine
Recombinant Human Papillomavirus Bivalent Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05237947 | Mar 2022 → Aug 2026 overdue | cervical carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Papillomavirus Bivalent Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05237947 ↗ |
| Modality | Vaccine | “recombinant human papillomavirus bivalent vaccine (Cervarix)” NCT05237947 ↗ |
| Route | Intramuscular | “Given IM” NCT05237947 ↗ |